...
首页> 外文期刊>Molecular & cellular proteomics: MCP >Identification of new autoantigens for primary biliary cirrhosis using human proteome microarrays
【24h】

Identification of new autoantigens for primary biliary cirrhosis using human proteome microarrays

机译:使用人类蛋白质组微阵列鉴定用于原发性胆汁性肝硬化的新自身抗原

获取原文
获取原文并翻译 | 示例
           

摘要

Primary biliary cirrhosis (PBC) is a chronic cholestatic liver disease of unknown etiology and is considered to be an autoimmune disease. Autoantibodies are important tools for accurate diagnosis of PBC. Here, we employed serum profiling analysis using a human proteome microarray composed of about 17,000 full-length unique proteins and identified 23 proteins that correlated with PBC. To validate these results, we fabricated a PBC-focused microarray with 21 of these newly identified candidates and nine additional known PBC antigens. By screening the PBC microarrays with additional cohorts of 191 PBC patients and 321 controls (43 autoimmune hepatitis, 55 hepatitis B virus, 31 hepatitis C virus, 48 rheumatoid arthritis, 45 systematic lupus erythematosus, 49 systemic sclerosis, and 50 healthy), six proteins were confirmed as novel PBC autoantigens with high sensitivities and specificities, including hexokinase-1 (isoforms I and II), Kelch-like protein 7, Kelch-like protein 12, zinc finger and BTB domain-containing protein 2, and eukaryotic translation initiation factor 2C, subunit 1. To facilitate clinical diagnosis, we developed ELISA for Kelch-like protein 12 and zinc finger and BTB domain-containing protein 2 and tested large cohorts (297 PBC and 637 control sera) to confirm the sensitivities and specificities observed in the microarray-based assays. In conclusion, our research showed that a strategy using high content protein microarray combined with a smaller but more focused protein microarray can effectively identify and validate novel PBC-specific autoantigens and has the capacity to be translated to clinical diagnosis by means of an ELISAbased method.
机译:原发性胆汁性肝硬化(PBC)是一种病因不明的慢性胆汁淤积性肝病,被认为是自身免疫性疾病。自身抗体是准确诊断PBC的重要工具。在这里,我们使用了由约17,000个全长独特蛋白质组成的人类蛋白质组微阵列进行的血清谱分析,并鉴定了23种与PBC相关的蛋白质。为了验证这些结果,我们用21个这些新近鉴定的候选物和9个其他已知的PBC抗原制造了PBC聚焦微阵列。通过对191名PBC患者和321名对照(43例自身免疫性肝炎,55例乙型肝炎病毒,31例丙型肝炎病毒,48例类风湿性关节炎,45例系统性红斑狼疮,49例系统性硬化症和50例健康人群)的其他队列进行PBC芯片筛选被确认为具有高度敏感性和特异性的新型PBC自身抗原,包括己糖激酶-1(I和II型),Kelch样蛋白7,Kelch样蛋白12,锌指和含BTB结构域的蛋白2以及真核翻译起始因子2C,亚基1。为促进临床诊断,我们开发了ELISA方法用于Kelch样蛋白12和含锌指和含BTB结构域的蛋白2,并测试了大型队列(297 PBC和637对照血清),以确认在该组中观察到的敏感性和特异性。基于微阵列的检测。总而言之,我们的研究表明,将高含量蛋白质微阵列与更小但更具针对性的蛋白质微阵列结合使用的策略可以有效地识别和验证新型PBC特异性自身抗原,并具有通过基于ELISA的方法转化为临床诊断的能力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号